Search Results for "Drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug. Results 1621 to 1630 of 2593 total matches.

In Brief: Fexofenadine (Allegra) and Fruit Juice

   
The Medical Letter on Drugs and Therapeutics • May 30, 2011  (Issue 1365)
The Medical Letter® On Drugs and Therapeutics Volume 53 (Issue 1365) May 30, 2011 ...
Fexofenadine (Allegra, and others) is the most recent second-generation H1-antihistamine to become available over the counter (OTC). Cetirizine (Zyrtec, and others) and loratadine (Claritin, and others) are already available OTC. Cetirizine can be sedating in usual doses. Loratadine can be sedating in higher-than-usual doses. Fexofenadine remains nonsedating even in higher doses.
Med Lett Drugs Ther. 2011 May 30;53(1365):41 |  Show IntroductionHide Introduction

Clarification: Vitamin E

   
The Medical Letter on Drugs and Therapeutics • Mar 19, 2012  (Issue 1386)
The Medical Letter® On Drugs and Therapeutics Volume 54 (Issue 1386) March 19, 2012 ...
The recent Medical Letter article on vitamin supplements1 included 2 sentences on vitamin E that could be misleading. "Vitamin E in food, which is mostly gamma-tocopherol, acts as an antioxidant. Vitamin E in supplements is mostly alpha-tocopherol, which may block the anti-oxidant effect of gamma-tocopherol and may have a pro-oxidant effect in vivo."Gamma-tocopherol is the most common form of vitamin E in the North American diet, and supplements are mostly alpha-tocopherol, which can, under some conditions, have a pro-oxidant effect. However, there is no evidence that taking supplements can...
Med Lett Drugs Ther. 2012 Mar 19;54(1386):24 |  Show IntroductionHide Introduction

Anistreplase for Acute Coronary Thrombosis

   
The Medical Letter on Drugs and Therapeutics • Feb 23, 1990  (Issue 812)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Anistreplase (Eminase - SmithKline Beecham, Upjohn), a plasminogen activator also known as APSAC, was recently approved by the US Food and Drug Administration (FDA) for intravenous (IV) thrombolytic treatment of coronary thrombosis. Three other thrombolytic agents - intracoronary urokinase (Abbokinase) and intracoronary or intravenous streptokinase (Streptase; Kabikinase) and alteplase (TPA; Activase)- were previously approved for coronary thrombolysis (Medical Letter, 29:107, 1987).
Med Lett Drugs Ther. 1990 Feb 23;32(812):15-6 |  Show IntroductionHide Introduction

Sapropterin (Kuvan) for Phenylketonuria

   
The Medical Letter on Drugs and Therapeutics • Jun 02, 2008  (Issue 1287)
Letter ® On Drugs and Therapeutics Volume 50 (Issue 1287) June 2, 2008 www.medicalletter.org ...
Sapropterin (Kuvan - BioMarin) has been approved by the FDA to reduce phenylalanine plasma concentrations in patients with phenylketonuria (PKU). PKU is a rare genetic disorder (it occurs in 1 in 8000 Caucasian and 1 in 50,000 African-American newborns) caused by a deficiency of phenylalanine hydroxylase (PAH) the resulting high levels of the amino acid in blood and urine lead to cognitive, behavioral and other neurological complications.
Med Lett Drugs Ther. 2008 Jun 2;50(1287):43-4 |  Show IntroductionHide Introduction

Advertisements for TNF Inhibitors

   
The Medical Letter on Drugs and Therapeutics • Nov 17, 2008  (Issue 1299)
Letter ® On Drugs and Therapeutics Volume 50 (Issue 1299) November 17, 2008 www.medicalletter.org ...
Some tumor necrosis factor (TNF) inhibitors are being promoted on the internet directly to the public for use in psoriasis (www.yahoo.com).
Med Lett Drugs Ther. 2008 Nov 17;50(1299):89 |  Show IntroductionHide Introduction

Linagliptin (Tradjenta) - A New DPP-4 Inhibitor for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Jun 27, 2011  (Issue 1367)
Letter® On Drugs and Therapeutics Volume 53 (Issue 1367) June 27, 2011 www.medicalletter.org ...
Linagliptin (Tradjenta – Boehringer Ingelheim/Lilly), a third oral dipeptidyl peptidase-4 (DPP-4) enzyme inhibitor, was recently approved by the FDA for treatment of type 2 diabetes, either alone or in combination with metformin, a sulfonylurea or pioglitazone
Med Lett Drugs Ther. 2011 Jun 27;53(1367):49-50 |  Show IntroductionHide Introduction

Golimumab (Simponi) for Ulcerative Colitis

   
The Medical Letter on Drugs and Therapeutics • Mar 31, 2014  (Issue 1439)
The Medical Letter® On Drugs and Therapeutics Published by The Medical Letter, Inc. • 145 ...
The FDA has approved golimumab (Simponi – Janssen), a fully human monoclonal antibody specific for tumor necrosis factor (TNF) alpha, for induction and maintenance of remission in patients with moderate to severe ulcerative colitis who do not respond to or cannot tolerate other therapies or who require continuous treatment with corticosteroids. Golimumab was approved earlier for treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. It is the third TNF inhibitor to be approved for use in ulcerative colitis.
Med Lett Drugs Ther. 2014 Mar 31;56(1439):25-6 |  Show IntroductionHide Introduction

Three More Immune Checkpoint Inhibitors for Advanced Bladder Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Dec 04, 2017  (Issue 1535)
chemotherapy. All of these drugs received accelerated approvals from the FDA based on tumor response rates ...
The FDA has approved avelumab (Bavencio – EMD Serono) and durvalumab (Imfinzi – AstraZeneca), two new immune check point inhibitors, and pembrolizumab (Keytruda – Merck), a checkpoint inhibitor that has been available in the US since 2014, for treatment of locally advanced or metastatic bladder cancer. Nivolumab (Opdivo) and atezolizumab (Tecentriq) were approved earlier for this indication.
Med Lett Drugs Ther. 2017 Dec 4;59(1535):e202-3 |  Show IntroductionHide Introduction

Insulins for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • May 06, 2019  (Issue 1571)
Insulins for Type 2 Diabetes The goal of drug therapy for type 2 diabetes is to achieve ...
The goal of drug therapy for type 2 diabetes is to achieve and maintain a near-normal glycated hemoglobin (A1C) concentration without inducing hypoglycemia; for most patients, the target A1C is <7%. Metformin is the preferred first-line treatment, but most patients with type 2 diabetes eventually require multidrug therapy and/or insulin to achieve glycemic control.
Med Lett Drugs Ther. 2019 May 6;61(1571):65-8 |  Show IntroductionHide Introduction

In Brief: A New Albuterol Inhaler (ProAir RespiClick) for Asthma

   
The Medical Letter on Drugs and Therapeutics • Oct 26, 2015  (Issue 1480)
The Medical Letter® on Drugs and Therapeutics Objective Drug Reviews Since 1959 Volume 57 (Issue ...
The short-acting beta2-agonist albuterol sulfate is now available as a dry powder for inhalation (ProAir RespiClick – Teva) for prevention and treatment of broncho spasm in patients ≥12 years old. ProAir RespiClick is the only short-acting beta2-agonist dry powder inhaler available in the US.Metered-dose inhalers (MDIs) use a hydrofluoroalkane (HFA) propellant. They require coordination of inhalation with actuation; using them with a valved holding chamber minimizes this need, but decreases portability because of the size of the chamber. Dry powder inhalers such as ProAir RespiClick, which...
Med Lett Drugs Ther. 2015 Oct 26;57(1480):150 |  Show IntroductionHide Introduction